Mammary Cell News 9.17 May 4, 2017 | |
| |
TOP STORYInvestigators examined the functional involvement and signaling mechanisms of melanoma-associated antigen A1 (MAGEA1) in breast and ovarian cancer cells. Inhibitory effects of MAGEA1 on cell proliferation and migration were observed using both gain-of- and loss-of-function approaches in breast and ovarian cancer cell lines. [Oncogene] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHThe authors found that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands during the acquisition of drug resistance. In the absence of the drug, the resistant CD49f+ population shrinks and taxane sensitivity is restored. [Stem Cell Reports] Full Article | Graphical Abstract Researchers focused on the role of delta-like homolog (DLK)1 in the control of breast cancer cell growth, a tumor type in which NOTCH receptors have been shown to play both opposite roles. They found that human DLK1 inhibits NOTCH signaling in MDA-MB-231 breast cancer cells. [FASEB J] Abstract Scientists performed global mapping of accessible chromatin in the mouse mammary gland epithelial EpH4 cell line and its Ras-transformed derivative (EpRas) using formaldehyde-assisted isolation of regulatory element-sequencing. Transforming growth factor (TGF)-β and Ras altered chromatin accessibility either cooperatively or independently, and AP1, ETS, and RUNX binding motifs were enriched in the accessible chromatin regions of EpH4 and EpRas cells. [Sci Rep] Full Article Glabridin (GLA) attenuated angiogenesis by the suppression of miR-148a-mediated Wnt/β-catenin signaling pathway in two human breast cancer cell lines. GLA also upregulated the expression of miR-148a in a dose-dependent manner, miR-148a, which could directly target Wnt-3′-untranslated regions, and decreased the expression of Wnt1, leading to β-catenin accumulation in the membranes from the cytoplasm and nucleus. [BMC Cancer] Full Article Researchers found that TL-2-8 selectively inhibited the proliferation and decreased the viability of various cancer cells, and it displayed only slight cytotoxicity against normal MCF-10A and HEK-293 cells. [Acta Pharmacol Sin] Full Article MUC1 Facilitates Metabolomic Reprogramming in Triple-Negative Breast Cancer Mucin1 (MUC1) was stably overexpressed in MDA-MB-231 triple-negative breast cancer (TNBC) cells and stably knocked down in MDA-MB-468 cells. They performed liquid chromatography-coupled tandem mass spectrometry-assisted metabolomic analyses and physiological assays, which indicated significant alterations in the metabolism of TNBC cells due to MUC1 expression. [PLoS One] Full Article HER2-Positive Breast Cancer Cells Expressing Elevated FAM83A Are Sensitive to FAM83A Loss In a panel of HER2+ breast cancer (BC) cell lines, FAM83A expression was significantly increased in the trastuzumab-resistant derivatives relative to parental controls. shRNA-mediated ablation of FAM83A in the panel of HER2+ BC cell lines suppressed HER2+ BC cell growth in both 2D and 3D cell cultures, elevated apoptosis markers, and suppressed PI3K signaling. [PLoS One] Full Article The authors investigated the therapeutic effect and molecular mechanisms of dandelion extract in triple-negative breast cancer cell line. Dandelion extract significantly decreased MDA-MB-231 cell viability, triggered G2/M phase arrest and cell apoptosis. [J Ethnopharmacol] Abstract | Graphical Abstract CLINICAL RESEARCHDose-dense regimens are one of the preferred options for the adjuvant treatment of breast cancer patients with intermediate to high risk. The GAIN trial aimed at optimizing intense dose-dense strategies by evaluating drug combinations and the addition of capecitabine. [Ann Oncol] Abstract The ARTemis trial previously reported that addition of neoadjuvant bevacizumab to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide in HER2 negative breast cancer improved the pathological complete response rate. Researchers present disease-free and overall survival with central pathology review. [Ann Oncol] Abstract | |
| |
REVIEWSImmunotherapy for the Treatment of Breast Cancer The authors discuss different immunotherapeutic strategies that are currently being tested for the treatment of breast cancer: These strategies include: the blockade of immunological checkpoints, antitumor vaccines, adoptive T-cell transfer therapy, and adoptive immunotherapy with monoclonal antibodies. [Expert Opin Biol Ther] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSUS Defense Supports UQ Breast Cancer Research The US Department of Defense has committed more than A$1.3 million from its Breast Cancer Research Program to a Queensland study tackling the spread of tumors to the brain. [The University of Queensland] Press Release A new $21 million gift to the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania from alumni Mindy and Jon Gray will cement and propel Penn’s preeminence as a leader in research to improve treatment and prevention strategies for hereditary cancers. [Basser Center for BRCA at Penn Medicine (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSNIH to Limit the Amount of Grant Money a Scientist Can Receive For the first time, the US National Institutes of Health (NIH) will restrict the amount of funding that an individual scientist can hold at any one time, based on a new point system. The move is part of an ongoing effort to make obtaining grants easier for early and mid-career scientists, who face much tougher odds than their more-experienced colleagues. [Nature News] Editorial Researchers Frustrated by Italian Misconduct Probe More than five years ago, Italian police began investigating allegations of research misconduct in papers by Alfredo Fusco, a prominent cancer scientist in Naples. Researchers frustrated by the case’s slow progress have told Nature that there is strong evidence that dozens of papers may contain manipulated data — and that a commercial photography studio was called in to cut and paste images. They say they are speaking out about the magnitude of the allegations because of their increasing impatience with the slow pace of investigations by police and by academic authorities. [Nature News] Editorial How Science Fares in the U.S. Budget Deal Congress has finally reached a deal on spending bills for the 2017 fiscal year, which ends on 30 September. House of Representatives and Senate leaders announced last night that they expect lawmakers to vote this week on an agreement that wraps together all 12 appropriations bills that fund federal operations. For the past 7 months, the government has been operating under a continuing resolution that froze 2017 spending at most agencies at 2016 levels and generally prevented them from starting new programs. [ScienceInsider] Editorial
| |
EVENTSNEW Summit for Cancer Immunotherapy 2017 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Positions – Cancer Research (Baylor College of Medicine) Researcher – Tumor Microenvironment and Invasion Program (SUNY Upstate Medical University) Postdoctoral Research – Cancer Biology (University of Pennsylvania) Bioinformatics Scientist – Breast Cancer (Windber Research Institute) Postdoctoral Fellow – Breast Cancer Stem Cell (University of Kentucky) Postdoctoral Position – Metastatic Breast Cancer (Purdue University) Research Assistant/Associate – Breast Cancer Biology (Icahn School of Medicine at Mount Sinai) Postdoctoral Associate – Mammary Stem Cell and Cancer Biology (University of Miami) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|